Coloma Jason V sold $922K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.73 ($26.71–$27.09, $0.92M total) across 4 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the CEO’s scheduled open-market sale details (shares, price range, total value) and post-transaction holdings.
Market read
Traders may monitor for follow-on insider activity, but this filing alone does not change the company’s fundamentals.
What to watch
Indirect holdings and multiple small lots can reduce interpretability; traders may want to compare with prior insider activity frequency and total insider ownership trends.
Background
The article is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
Maze Therapeutics CEO Coloma Jason V sold $922,315 of MAZE shares via a 10b5-1 plan, with weighted prices $26.7140 to $27.0940.
Likely limited near-term impact; any effect would be sentiment-driven rather than a new business development.
The filing discloses transaction size and timing, but provides no new operational, regulatory, or financial information beyond the sale itself.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderColoma Jason V
CEO and director who executed the sale under a 10b5-1 plan.